Oncotarget


Oncotarget | MK256 is Novel CDK8 Inhibitor With Potent Antitumor Activity in AML Through Downregulation of STAT Pathway


FOR IMMEDIATE RELEASE
2022-11-10

“In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator both in vitro and in vivo in AML.”

 


BUFFALO, NY- November 10, 2022 –
A new research paper was published in Oncotarget's Volume 13 on November 2, 2022, entitled, “MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.”

Acute myeloid leukemia (AML) is the most lethal form of AML due to disease relapse. Cyclin dependent kinase 8 (CDK8) is a serine/threonine kinase that belongs to the family of Cyclin-dependent kinases and is an emerging target for the treatment of AML. MK256, a potent, selective, and orally available CDK8 inhibitor was developed to target AML. 

In this new study, researchers Jen-Chieh Lee, Shu Liu, Yucheng Wang, You Liang, and David M. Jablons from the University of California San Francisco and Touro University sought to examine the anticancer effect of MK256 on AML. 


“In CD34+/CD38- leukemia stem cells, we found that MK256 induced differentiation and maturation.”


Treatment of MK256 inhibited proliferation of AML cell lines. Further studies of the inhibitory effect suggested that MK256 not only downregulated phosphorylated STAT1(S727) and STAT5(S726), but also lowered mRNA expressions of MCL-1 and CCL2 in AML cell lines. Efficacy of MK256 was shown in MOLM-14 xenograft models, and the inhibitory effect on phosphorylated STAT1(S727) and STAT5(S726) with treatment of MK256 was observed in vivo. 


Pharmacologic dynamics study of MK256 in MOLM-14 xenograft models showed dose-dependent inhibition of the STAT pathway. Both
in vitro and in vivo studies suggested that MK256 could effectively downregulate the STAT pathway. In vitro ADME, pharmacological kinetics, and toxicity of MK256 were profiled to evaluate the drug properties of MK256. 


“Our results show that MK256 is a novel CDK8 inhibitor with a desirable efficacy and safety profile and has great potential to be a promising drug candidate for AML through regulating the STAT pathway.”


DOI:
https://doi.org/10.18632/oncotarget.28305 


Correspondence to:
Jen-Chieh Lee -
jenchieh.lee@ucsf.edu, and Shu Liu - shu.liu@ucsf.edu


Keywords:
AML, CDK8, kinase inhibitor, STAT pathway, xenograft

 


To learn more about
Oncotarget, visit Oncotarget.com and connect with us on social media:

Twitter - https://twitter.com/Oncotarget
Facebook - https://www.facebook.com/Oncotarget
YouTube – www.youtube.com/c/OncotargetYouTube
Instagram -
https://www.instagram.com/oncotargetjrnl/
LinkedIn -
https://www.linkedin.com/company/oncotarget/
Pinterest -
https://www.pinterest.com/oncotarget/
LabTube -
https://www.labtube.tv/channel/MTY5OA

SoundCloud - https://soundcloud.com/oncotarget

For media inquiries, please contact: media@impactjournals.com.

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)



Copyright © 2022 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC